An inhaled formulation of nintedanib — the active ingredient in Ofev — demonstrated enhanced antifibrotic effects after short-duration doses compared to oral formulations given at a higher dose in a rat model with induced idiopathic pulmonary…
News
Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis (IPF) with poorer lung function, a small real-world analysis has found. Age and lung function predicted the therapy’s efficacy in this group of patients. …
Research investigating the role of immune cells in triggering lung and heart rejection following transplant will be supported by $10 million in grants from the National Institutes of Health (NIH). The grants, awarded to scientists at Washington University School of Medicine in St. Louis, will support research that aims…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A Glimmer of Hope,” the competition is a means to “visually express the hope that exists for people affected by…
Japanese people diagnosed with both pulmonary fibrosis (PF) and emphysema appear to carry a single genetic mutation that contributes to the development of both conditions, a study reports. This mutation was linked to lower levels of the anti-inflammatory…
In the U.S., idiopathic pulmonary fibrosis (IPF) mortality rates decreased from 2004 to 2017, a new study shows. The data suggests the decline might be partly explained by a decline in smoking, but further research is needed to better understand the factors contributing to this trend. The study, “Mortality Trends…
Galecto‘s investigational compound GB0139, now in an enrolling clinical trial, has been designated an orphan drug by the U.S. Food and Drug Administration and the European Medicines Agency (EMA) as a potential treatment of idiopathic pulmonary fibrosis (IPF). GB0139 (formerly TD139) is an inhaled small molecule inhibitor of…
AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, exercising a licensing option under an earlier research partnership between the companies. Integrins control a wide variety of cellular processes, including…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…
Four years of monitoring clinical use of Ofev (nintedanib) by people with idiopathic pulmonary fibrosis (IPF) has found no new safety concerns, a database study found. Treatment safety and tolerability were consistent with findings reported in pivotal trials, with non-severe diarrhea continuing to be the most common side effect noted,…
